Virginia Medicaid and GLP-1 coverage

Virginia's service authorization form for weight-loss management, effective July 1, 2026, first requires the prescriber to attest "that the patient's obesity is disabling and life threatening," with participation in nutritional counseling and a physical activity program. For GLP-1 drugs it names Wegovy and Saxenda injections at a minimum age of 12, and the Wegovy tablet and Zepbound at 18, and requires "BMI > 40 kg/m2 if no applicable risk factors," or a body mass index over 37 "with one or more of the following risk factors: dyslipidemia, hypertension, or type 2 diabetes." Then: "Member has tried and failed one of the non-GLP1 weight-loss medications" or is intolerant to all of them, and is not on another GLP-1. An initial GLP-1 approval runs 6 months. A renewal needs at least 5% weight loss against the last authorization, and "Renewals will no longer be granted once a member reaches a BMI < 25."

Virginia Department of Medical Assistance Services, Service Authorization Form: Weight-Loss Management, effective July 2026 · source

Where the drugs sit on the list. In the preferred drug list dated July 1, 2025, the class is headed "Weight Management Agents CLOSED CLASS." Its preferred column holds orlistat, Xenical, phendimetrazine, phentermine, benzphetamine and diethylpropion. Its non-preferred column holds Imcivree, Lomaira, phentermine/topiramate, Saxenda, Wegovy and Zepbound.

Virginia Medicaid Pharmacy Benefits Management System, Virginia's Medicaid Preferred Drug List / Common Core Formulary (July 1, 2025 edition), effective July 2025 · source

The pharmacy manual, revised March 4, 2026, says "Drugs approved by the FDA for weight loss may be covered for members who meet specific criteria," and lists the documentation a request should carry, ending with "Documentation of the attending physician certifying the determination that the member's life is at risk due to obesity." It also settles the managed care question: "The PDL applies to all Medicaid members enrolled in in both fee-for service (FFS) and managed care organizations (MCOs)"; "For closed classes, both FFS and MCOs must cover the posted PDL exactly as identified"; and plans "are required to use the same service authorization criteria as the FFS program for drugs on the PDL," though how you submit the request may differ.

Virginia Department of Medical Assistance Services, Pharmacy Provider Manual, Chapter IV: Covered Services and Limitations, effective March 2026 · source

What the legislature told the agency to do. The enacted 2025 budget, in Item 288, paragraph TTTT.2, reads: "Effective July 1, 2025, ... the Department of Medical Assistance Services shall amend the State Plan for Medical Assistance Services and 12VAC30-50-520 to cover weight loss medication when prescribed for weight loss (i) in those instances where an individual has a body mass index (BMI) of 35 or greater ... or (ii) ... a BMI greater than 30 ... and has at least one of the following weight-related comorbid conditions: hypertension, Type II Diabetes Mellitus, or Dyslipidemia," after at least six months of a lifestyle program without a five percent weight reduction. The paragraph above it, TTTT.1, effective July 1, 2024, had set the floors at a BMI "greater than 40" or "greater than 37" with one of the same three conditions. The July 2026 form uses the 2024 numbers.

Virginia General Assembly, 2025 Appropriation Act (HB 1600, Chapter 725), Item 288, effective July 2025 · source

The 2026 budget makes the next set of criteria conditional. Item 291, paragraph MMMM, directs the agency to require service authorization for covered weight-loss drugs, to evaluate manufacturer programs and other arrangements for GLP-1 drugs, and to implement the one with the greatest savings "which results in a price per unit of $245 or less." If that is the federal BALANCE Model, coverage follows that model's criteria. If no arrangement reaches "a net price per one-month supply of $245 or less," the fallback is coverage at a BMI greater than 40, or greater than 37 with one of the same three conditions, with traditional weight-loss drugs covered as approved but "excluding Glucagon-like peptide-1 drugs and any other newer weight loss medications" from that third path. We looked for a bulletin saying which path the agency took and didn't find one: the two 2026 preferred-drug-list bulletins the agency published, dated April 1 and July 1, 2026, mention neither weight-loss coverage, the BALANCE Model nor a $245 price, though the April one notes that the Drug Utilization Review Board reviewed a GLP-1 receptor agonist utilization analysis at its December 11, 2025 meeting; the agency's bulletin index path returned 404 on September 1, 2026.

Virginia General Assembly, 2026 Appropriation Act (HB 30), Item 291 · source

The regulation the budgets tell the agency to amend still reads as it did in 1999. 12VAC30-50-520, headed "Drugs or drug categories which are not covered," opens with "Agents when used for anorexia or weight gain. Coverage of anorexiants for other than weight loss requires medical justification," and then says weight-loss drugs, "when preauthorized, will be covered for recipients who meet the strict disability standards for obesity established by the Social Security Administration in effect on April 7, 1999, and whose condition is certified as life threatening." Its historical note ends at an amendment effective September 1, 1999. The July 2026 form's "disabling and life threatening" attestation is that sentence surviving.

Virginia Law Library, Virginia Administrative Code 12VAC30-50-520, effective September 1999 · source · SA form

Which clock you're on depends on who denied you. For a decision by the agency itself: "A Request for Appeal shall be filed within 30 days of the appellant's receipt of the notice of an action or adverse determination," and "It is presumed that appellants will receive the notice five days after the agency mails the notice" unless you show otherwise. For a managed care plan's denial, the managed care rule says "Internal appeal requests must be submitted within 60 days from the date of the notice of adverse benefit determination," that "The member must exhaust the MCO's internal appeals process before appealing to the DMAS Appeals Division," and that the appeal to the state then has to be filed "within 120 days of the member's receipt of the MCO's internal appeal decision." Services already in place continue if the request is filed before the date of action.

Virginia Law Library, Virginia Administrative Code 12VAC30-110-160 (time limit for filing) and 12VAC30-120-420 (member grievances and appeals), effective May 2015 · source · 12VAC30-120-420